Surmodics (NASDAQ:SRDX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Surmodics (NASDAQ:SRDX) from a buy rating to a strong-buy rating in a report issued on Tuesday.

Separately, Needham & Company LLC restated a buy rating and issued a $47.00 target price on shares of Surmodics in a report on Wednesday, April 10th.

Surmodics Stock Up 0.4 %

Shares of SRDX opened at $26.49 on Tuesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.97 and a current ratio of 4.84. Surmodics has a one year low of $16.79 and a one year high of $39.41. The stock has a market capitalization of $377.22 million, a price-to-earnings ratio of 69.71 and a beta of 1.01. The stock has a 50 day moving average price of $29.42 and a 200 day moving average price of $31.85.

Institutional Trading of Surmodics

Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its holdings in Surmodics by 305.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 775 shares of the company’s stock valued at $25,000 after buying an additional 584 shares in the last quarter. UBS Group AG lifted its stake in shares of Surmodics by 141.1% in the 3rd quarter. UBS Group AG now owns 2,290 shares of the company’s stock valued at $70,000 after purchasing an additional 1,340 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of Surmodics by 24.3% in the 1st quarter. Captrust Financial Advisors now owns 2,307 shares of the company’s stock valued at $105,000 after purchasing an additional 451 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Surmodics in the 3rd quarter valued at $87,000. Finally, Citigroup Inc. lifted its stake in shares of Surmodics by 1,023.0% in the 2nd quarter. Citigroup Inc. now owns 4,144 shares of the company’s stock valued at $130,000 after purchasing an additional 3,775 shares during the last quarter. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).